Adjuvants are components of vaccines that help to enhance the magnitude, breadth, and duration of the immune response to vaccination
The company's SaaS solutions are tailored to enhance accessibility, efficiency, and patient-centricity in healthcare operations
The company is committed to a new category development in areas like adult Immunization with products like Shingrix to make a positive impact to the lives of the patients in India
Zydus’s revenue growth was led by India and EU formulations businesses in addition to that in the emerging markets.
Revenue from Operations stood at Rs. 2,607 crore, 25% YoY growth. Domestic revenue at Rs. 2,400 crore, 20% YoY growth and export revenue at Rs. 207 crore, 118% YoY growth
For 9 months period ended December 2023, the company’s PAT up 16% to Rs 330 crores (before exceptional items)
The company also plans to boost its India presence by adding 1,500 beds in the next 2-3 years
Inducts advanced AI-Powered 24x7 remote patient monitoring system
He is also inducted as a member of the management council and senior management personnel of the company
Subscribe To Our Newsletter & Stay Updated
